These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12125626)

  • 1. Anti-HIV agents. TXU-PAP--early results.
    TreatmentUpdate; 2000 Feb; 12(1):2. PubMed ID: 12125626
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
    Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
    Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HIV agents. A warning about high viral loads.
    TreatmentUpdate; 2003; 15(7):1-2. PubMed ID: 17216865
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiretroviral rounds. CD4 count 423, viral load 12,000: time to treat anyway?
    Hodder S; Frank I
    AIDS Clin Care; 2006 Jun; 18(6):59-60. PubMed ID: 16791955
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agents. Alternating regimens look promising.
    TreatmentUpdate; 2003; 15(5):2-3. PubMed ID: 17216855
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. How long will a first regimen last?
    TreatmentUpdate; 2003; 15(5):1-2. PubMed ID: 17219614
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical study on treatment of HIV infected persons based on viral load detection and CD4+ T lymphocyte counting].
    Lin X; Xu L; Feng Y; Li J; Pei L; Shen T; Shao Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):211-4. PubMed ID: 12665921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV agents. Is FOTO a treatment interruption that works?
    TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661
    [No Abstract]   [Full Text] [Related]  

  • 13. Complications & side effects. Can statins be used as anti-HIV drugs?
    TreatmentUpdate; 2004; 16(7):9. PubMed ID: 17219689
    [No Abstract]   [Full Text] [Related]  

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy for early HIV infection: how far back should the pendulum swing?
    Schechter M
    J Infect Dis; 2004 Sep; 190(6):1043-5. PubMed ID: 15319851
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV agents. Can valproic acid help flush HIV from hiding?
    TreatmentUpdate; 2005; 17(6):4-5. PubMed ID: 17228475
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral suppression of HIV in the context of persistently low CD4 counts: new insights.
    Laurence J
    AIDS Read; 2007 Jan; 17(1):7, 18. PubMed ID: 17274141
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-HIV agents. Receptor blocker (SCH 532706) enters clinical trials.
    TreatmentUpdate; 2008 Mar; 20(2):8-9. PubMed ID: 18663778
    [No Abstract]   [Full Text] [Related]  

  • 20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.